US Patent No: 5,585,479

Number of patents in Portfolio can not be more than 2000

Antisense oligonucleotides directed against human ELAM-I RNA

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

The present invention provides a method for the treatment of septic shock d inflammatory complications of shock. A process for selectively inhibiting the expression of the human ELAM-I mRNA transcript using at least one oligonucleotide which is substantially complementary to at least a portion of the ELAM-I gene is disclosed, as are composition comprising the oligonucleotide.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVYARLINGTON, VA10912

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bradley, Matthews O Laytonsville, MD 17 572
Hoke, Glenn D Mt. Airy, MD 7 278
Lee, Che-Hung Silver Spring, MD 5 265
Williams, Taffy J Lansdale, PA 10 291

Cited Art

Patent Info (Count) # Cites Year
 
BIOGEN IDEC MA INC. (1)
5,272,263 DNA sequences encoding vascular cell adhesion molecules (VCAMS) 34 1989

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (22)
5,843,737 Cancer associated gene protein expressed therefrom and uses thereof 3 1994
5,990,088 Method for treating kaposi's sarcoma with antisense oligonucleotides 9 1995
5,734,016 Fuse binding protein and method for inhibiting expression of fuse binding protein 4 1996
6,207,646 Immunostimulatory nucleic acid molecules 184 1996
5,998,602 RNase L activators and antisense oligonucleotides effective to treat RSV infections 13 1997
6,072,031 Cellular apoptosis susceptibility protein (CSP) 5 1997
6,239,116 Immunostimulatory nucleic acid molecules 159 1997
6,156,564 Cellular apoptosis susceptibility protein (CSP) and antisense CSP 2 1997
6,232,086 Method for detecting cancer cells 4 1999
6,653,292 Method of treating cancer using immunostimulatory oligonucleotides 82 1999
6,977,245 Oligodeoxynucleotide and its use to induce an immune response 27 2002
7,521,063 Multiple CPG oligodeoxynucleotides and their use to induce an immune response 15 2002
7,354,909 Method for rapid generation of mature dendritic cells 14 2002
7,713,529 Methods for treating and preventing infectious disease 20 2002
7,615,227 Use of CpG oligodeoxynucleotides to induce angiogenesis 14 2002
8,263,091 Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides 1 2003
8,008,266 Methods of treating cancer using immunostimulatory oligonucleotides 13 2003
8,309,527 Immunomodulatory oligonucleotides 0 2004
7,960,356 Oligodeoxynucleotide and its use to induce an immune response 6 2005
7,935,351 Use of CPG oligodeoxynucleotides to induce angiogenesis 10 2007
7,959,934 Method for rapid generation of mature dendritic cells 8 2008
8,227,446 Oligodeoxynucleotide and its use to induce an immune response 1 2011
 
UNIVERSITY OF IOWA RESEARCH FOUNDATION (15)
5,962,425 Methods for decreasing the expression of specifically targeted genes 18 1995
6,214,806 Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders 118 1998
6,339,068 Vectors and methods for immunization or therapeutic protocols 130 1998
6,429,199 Immunostimulatory nucleic acid molecules for activating dendritic cells 131 1998
6,218,371 Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines 116 1999
6,406,705 Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant 142 1999
7,935,675 Immunostimulatory nucleic acid molecules 13 1999
6,949,520 Methods related to immunostimulatory nucleic acid-induced interferon 56 2000
7,534,772 Methods for enhancing antibody-induced cell lysis and treating cancer 22 2001
6,821,957 Vectors and methods for immunization or therapeutic protocols 47 2001
8,202,688 Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant 5 2002
7,223,741 Immunostimulatory nucleic acid molecules 39 2003
7,524,828 Immunostimulatory nucleic acid molecules 21 2004
7,776,344 Methods related to immunostimulatory nucleic acid-induced interferon 16 2005
7,888,327 Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions 11 2009
 
ISIS PHARMACEUTICALS, INC. (14)
5,792,844 Oligonucleoside linkages containing adjacent nitrogen atoms 20 1994
5,948,898 Methoxyethoxy oligonucleotides for modulation of protein kinase C expression 4 1996
5,856,099 Antisense compositions and methods for modulating type I interleukin-1 receptor expression 5 1996
5,789,573 Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 41 1996
5,952,229 Antisense oligonucleotide modulation of raf gene expression 5 1996
6,077,833 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein 16 1996
5,985,558 Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos 29 1997
5,981,731 Antisense oligonucleotide modulation of B-raf gene expression 7 1997
6,093,811 Oligonucleotide modulation of cell adhesion 0 1997
6,214,551 Oligonucleoside linkages containing adjacent nitrogen atoms 8 1998
6,153,599 Methoxyethoxy oligonucleotides for modulation of protein kinase C expression 0 1999
6,312,900 Antisense oligonucleotide compositions and methods for the modulation of activating protein 1 3 1999
6,753,423 Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals 3 2000
7,115,580 Antisense modulation of B7 protein expression 2 2000
 
THE JOHNS HOPKINS UNIVERSITY (13)
5,994,119 Mammalian regulator of nonsense-mediated RNA decay 4 1996
5,994,618 Growth differentiation factor-8 transgenic mice 31 1997
6,008,434 Growth differentiation factor-11 transgenic mice 2 1997
6,673,534 Methods for detection of mutations in myostatin variants 8 1997
6,048,965 Mammalian regulator of nonsense-mediated RNA decay 0 1999
6,465,239 Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species 13 1999
6,468,535 Growth differentiation factor-8 16 1999
6,517,835 Growth differentiation factor-11 5 1999
7,381,528 Methods for detection of mutations in myostatin variants 11 2003
7,332,575 Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species 2 2004
7,976,839 Growth differentiation factor-11 0 2008
8,323,964 Polynucleotides encoding promyostatin polypeptides 0 2008
7,732,571 Chicken growth differentiation factor-8 0 2008
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (7)
5,883,082 Compositions and methods for preventing and treating allograft rejection 10 1994
5,925,333 Methods for modulation of lipid uptake 26 1995
5,786,213 Inhibition of endogenous gastrin expression for treatment of colorectal cancer 5 1996
7,309,692 Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 0 1996
6,165,990 Antisense polynucleotide 3 1998
7,220,853 Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1 0 2002
7,923,548 Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1 0 2007
 
RIGEL PHARMACEUTICALS, INC. (7)
6,824,976 Method for selective inactivation of viral replication 9 2000
6,777,179 Method for selective inactivation of viral replication 11 2002
6,623,961 Method for selective inactivation of viral replication 11 2002
6,579,674 Method for selective inactivation of viral replication 6 2002
7,045,284 Method for selective inactivation of viral replication 7 2004
7,285,383 Method for selective inactivation of viral replication 5 2005
7,432,047 Method for selective inactivation of viral replication 0 2006
 
THOMAS JEFFERSON UNIVERSITY (7)
5,962,220 Compositions that specifically bind to colorectal cells and methods of using the same 10 1995
5,861,502 Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen 5 1995
6,087,109 Compositions that specifically bind to colorectal cancer cells and methods of using the same 3 1998
7,744,870 ST receptor binding compounds and methods of using the same 1 2000
6,767,704 Methods of screening and diagnosing esophageal cancer by determining guanylin cyclase C expression 6 2001
7,854,933 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin 1 2004
8,067,007 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin 0 2010
 
DAIICHI SANKYO COMPANY, LIMITED (6)
7,527,790 Methods of reducing bone absorption comprising administering an antibody that binds OBM 6 2002
6,855,808 Proteins and methods for producing the proteins 2 2002
7,192,718 Methods for identifying a substance which specifically binds to an osteoclastogenesis inhibitory factor-binding molecule and modulates the biological activity thereof 6 2003
7,276,344 Methods for using the osteoclastogenesis inhibitory factor (OCIF) protein 0 2004
7,449,185 Antibodies to OCIF-binding molecules 6 2004
7,468,268 Nucleic acid molecules encoding osteoclastogenesis inhibitory factor proteins 0 2004
 
IDERA PHARMACEUTICALS, INC. (6)
5,801,235 Oligonucleotides with anti-cytomegalovirus activity 0 1994
5,801,156 Inhibition of neovascularization using VEGF-specific oligonucleotides 9 1995
5,710,136 Inhibition of neovascularization using VEGF-specific oligonucleotides 8 1995
6,306,829 Modified VEGF oligonucleotides for treatment of skin disorders 0 1996
6,984,729 Oligonucleotides specific for hepatitis B virus 1 1997
6,649,596 Modified VEGF Oligonucleotides for Inhibition of tumor growth 0 1998
 
INSTITUTE OF VIROLOGY, SLOVAK ACADEMY OF SCIENCES (6)
6,774,117 MN gene and protein 3 1994
6,069,242 MN gene and protein 9 1995
6,027,887 MN gene and protein 16 1997
6,297,041 MN gene and protein 7 1998
6,297,051 MN gene and protein 7 1998
7,115,715 Anti-idiotype antibodies to MN proteins and MN polypeptides 2 2001
 
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (5)
6,245,747 Targeted site specific antisense oligodeoxynucleotide delivery method 10 1998
6,117,858 Compositions and methods for altering the biodistribution of biological agents 7 1998
6,686,338 Enzyme inhibitors for metabolic redirection 7 2000
6,537,814 Compositions and methods for altering the biodistribution of biological agents 2 2000
6,673,778 Enzyme inhibitors for metabolic redirection 5 2000
 
IMMUNEX CORPORATION (4)
7,411,050 Monoclonal blocking antibody to human RANKL 9 2004
7,932,375 Kits for detecting rank nucleic acids 3 2007
7,744,886 Methods for interfering with rank signaling 5 2008
8,377,690 Cells and methods for producing blocking antibodies to human RANKL 0 2010
 
INSTITUTE OF VIROLOGY OF THE SLOVAK ACADEMY OF SCIENCES (4)
7,713,704 MN gene and protein 0 1999
7,910,549 MN gene and protein 0 2006
7,910,691 MN gene and protein 0 2007
7,855,185 MN gene and protein 0 2007
 
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (4)
5,831,066 Regulation of bcl-2 gene expression 17 1995
7,022,831 Regulation of BCL-2 gene expression 82 1999
6,841,541 Regulation of BCL-2-gene expression 0 2000
6,414,134 Regulation of bcl-2 gene expression 18 2000
 
UNIVERSITY OF MARYLAND, BALTIMORE (4)
6,313,277 Breast cancer resistance protein (BCRP) and the DNA which encodes it 5 1999
7,541,437 Breast cancer resistance protein (BCRP) and the DNA which encode it 1 2001
7,655,755 Breast cancer resistance protein (BCRP) and the DNA which encodes it 0 2005
7,741,445 Breast cancer resistance protein (BCRP) antibodies 0 2008
 
AEGERA THERAPEUTICS INC. (3)
6,107,088 XAF genes and polypeptides: methods and reagents for modulating apoptosis 5 1998
6,495,339 Method of identifying a compound that modulates XAF-mediated apoptosis 0 2000
6,946,544 XAF genes and polypeptides: methods and reagents for modulating apoptosis 4 2002
 
ALTON OCHSNER MEDICAL FOUNDATION (3)
5,936,079 Oligonucleotide which binds to a chromosomal binding site for p53 protein 0 1994
6,303,328 Inhibition of cellular proliferation in vitro by oligonucleotide binding to a chromosomal binding site for p53 protein 1 1999
6,645,944 Inhibition of cellular proliferation by oligonucleotide binding to a chromosomal binding site for p53 protein 1 2001
 
AMGEN INC. (3)
6,284,740 Osteoprotegerin 20 1997
7,807,795 Antibodies to osteoprotegerin binding proteins 1 1998
7,923,008 Methods for decreasing osteoclast formation or bone resorption using an antibody to osteoprotegerin binding protein 3 2006
 
BAYER BIOSCIENCE GMBH (3)
7,176,190 Plants which synthesize a modified starch, process for the production thereof and modified starch 0 2003
7,897,760 Plants which synthesize a modified starch, process for the production thereof and modified starch 0 2006
7,569,744 Plants which synthesize a modified starch, process for the production thereof and modified starch 0 2006
 
GEN-PROBE INCORPORATED (3)
5,733,781 Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus 2 1994
5,716,846 Method for inhibiting cellular proliferation using antisense oligonucleotides to interleukin-6 receptor mRNA 2 1995
5,945,336 Oligonucleotides and methods for inhibiting cellular proliferation 1 1997
 
TAKARA SHUZO CO., LTD. (3)
5,773,274 Gene encoding sulfotransferase 0 1997
5,965,419 Purified sulfotransferase 0 1998
6,020,467 Antibodies against sulfotransferase 0 1999
 
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (3)
5,858,774 Antisense DNA constructs for expression of hybrid MRNAs driven by inducible, tissue-specific promoters 13 1995
6,007,991 Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer 23 1997
6,133,245 Antisense DNA constructs for expression of hybrid mRNAs driven by inducible, tissue-specific promoters 1 1998
 
AVENTIS PHARMA S.A. (2)
6,180,362 Peptides which inhibit ras protein activity, their preparation and use 1 1995
5,856,435 Nucleic acid-containing composition, its preparation and use 12 1996
 
BETAGENE, INC. (2)
5,891,717 Methods and compositions for inhibiting hexokinase 15 1996
5,854,067 Hexokinase inhibitors 27 1996
 
COLEY PHARMACEUTICAL GROUP, INC. (2)
6,727,230 Immune stimulation by phosphorothioate oligonucleotide analogs 46 1998
7,585,847 Immunostimulatory nucleic acids for the treatment of asthma and allergy 24 2001
 
CORNELL RESEARCH FOUNDATION, INC. (2)
6,093,806 DNA encoding proteins of Kaposi's sarcoma associated herpesvirus 0 1996
6,120,993 5-oxoprolinase 1 1996
 
DANA-FARBER CANCER INSTITUTE, INC. (2)
5,962,224 Isolated DNA encoding p62 polypeptides and uses therefor 3 1995
5,994,070 Trio molecules and uses related thereto 1 1997
 
EAST CAROLINA UNIVERSITY (2)
6,025,339 Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation 14 1996
7,034,007 Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion 10 2003
 
INCYTE PHARMACEUTICALS, INC. (2)
5,869,633 Thrombin receptor homolog polynucleotide 0 1997
6,143,870 Thrombin receptor homolog 0 1998
 
MEDAREX, INC. (2)
7,718,776 Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors 6 2003
8,367,063 Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors 0 2010
 
METHYLGENE, INC. (2)
6,020,318 DNA methyltransferase genomic sequences and antisense oligonucleotides 4 1997
6,221,849 DNA methyltransferase genomic sequences and antisense oligonucleotides 2 1998
 
MURDOCH CHILDRENS RESEARCH INSTITUTE (2)
5,929,040 Method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders 24 1996
6,284,741 Method for the prophylaxis and/or treatment of proliferative and /or inflammatory skin disorders 9 1998
 
NOVARTIS AG (2)
6,018,042 Antitumor antisense oligonucleotides 9 1997
6,776,986 Inhibition of HIV-1 replication by antisense RNA expression 0 1998
 
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2)
6,258,557 Smooth muscle cell LIM promoter 0 1997
6,514,935 Methods of treating hypertension 1 1999
 
RAMOT AT TEL AVIV UNIVERSITY LTD. (2)
6,503,752 Lymphotropic agents and vectors 1 1996
5,882,880 Human checkpoint gene and gene for antisense RNA thereof 1 1997
 
THE PENN STATE RESEARCH FOUNDATION (2)
5,914,269 Oligonucleotide inhibition of epidermal growth factor receptor expression 5 1997
6,187,585 Oligonucleotide inhibition of epidermal growth factor receptor expression 4 1999
 
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (2)
5,872,241 Multiple component RNA catalysts and uses thereof 10 1995
6,677,152 Reversal of cancer phenotype by inhibiting expression of prostate tumor inducing gene 1 1999
 
THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (2)
5,837,694 Method for enhancing neurone survival and agents useful for same 4 1996
6,174,869 Method for enhancing neurone survival and agents useful for same 1 1998
 
TRUSTEES OF BOSTON UNIVERSITY (2)
7,094,766 Use of locally applied DNA fragments 8 2000
8,183,222 Method to inhibit cell growth using oligonucleotides 0 2010
 
UNISEARCH LIMITED (2)
5,849,573 Nucleotide sequence encoding carbamoyl phosphate synthetase II 0 1995
6,183,996 Nucleotide sequence encoding carbamoyl phosphate synthetase II 0 1998
 
UNIVERSITY OF MASSACHUSETTS (2)
5,837,854 Oligonucleotides with anti-Epstein-Barr virus activity 0 1996
5,726,020 Inhibition of II synthesis 2 1996
 
YEDA RESEARCH AND DEVELOPMENT CO. LTD. (2)
5,968,816 Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins 0 1996
7,374,909 Modulators of intracellular inflammation, cell death and cell survival pathways 0 1998
 
BASF AKTIENGESELLSCHAFT (1)
5,756,697 Subunits of glutamate receptors, their preparation and their use 0 1996
 
BAXTER INTERNATIONAL INC. (1)
6,774,227 Therapeutic uses of factors which inhibit or neutralize MIF activity 1 1996
 
BAYER CROPSCIENCE AG (1)
5,981,181 DNA sequences with oligosaccharide transporter, plasmids bacteria and plants containing a transporter as well as a process for the preparation and transformation of yeast strains for identification of the transporter 2 1997
 
BAYER HEALTHCARE LLC (1)
8,334,137 MN gene and protein 0 2010
 
BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH (1)
7,326,783 Pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms 0 1994
 
CENTRE DE RECHERCHE DU CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (1)
5,821,354 Radiolabeled DNA oligonucleotide and method of preparation 1 1996
 
CHUGAI SEIYAKU KABUSHIKI KAISHA (1)
6,596,537 Human interleukin-6 receptor expression inhibitor 0 1997
 
COMPUGEN LTD. (1)
6,740,516 Nucleic acid and amino acid sequences 4 2001
 
CONSIGLIO NAZIONALE DELLE RICERCHE (1)
6,005,095 Antisense transcript associated to tumor cells having a T(14;18) translocation and oligodeoxynucleotides useful in the diagnosis and treatment of said tumor cells 17 1997
 
CORN PRODUCTS DEVELOPMENT, INC. (1)
6,103,893 High amylose starch from transgenic potato plants 19 1996
 
CPG IMMUNO PHARMACEUTICALS GMBH (1)
7,001,890 Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination 48 1998
 
CPG IMMUNOPHARMACEUTICALS, INC. (1)
6,194,388 Immunomodulatory oligonucleotides 143 1995
 
CREATIVE BIOMOLECULES, INC. (1)
5,928,940 Morphogen-responsive signal transducer and methods of use thereof 10 1996
 
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (1)
5,948,901 Antisense oligonucleotides for aromatase inhibition 0 1996
 
FOX CHASE CANCER CENTER (1)
5,935,937 Compositions and methods for inducing apoptosis 7 1997
 
FRED HUTCHINSON CANCER RESEARCH CENTER (1)
5,739,310 Ribosomes as vectors for RNA 3 1996
 
GEORGETOWN UNIVERSITY (1)
7,267,977 Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer 0 1998
 
GERON CORPORATION (1)
5,876,979 RNA component of mouse, rat, Chinese hamster and bovine telomerase 16 1995
 
HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (1)
5,846,728 Oligonucleotide-polyamide conjugates 5 1997
 
ISTITUTO REGINA ELENA (1)
6,080,727 Oligonucleotide treatments and compositions for human melanoma 7 1997
 
JEWISH HOSPITAL AT WASHINGTON UNIVERSITY (1)
5,824,550 Voltage-gated calcium channel and antisense oligonucleotides thereto 1 1994
 
LA JOLLA CANCER RESEARCH FOUNDATION (1)
5,849,904 Isolated nucleic acid molecules which hybridize to polysialyl transferases 16 1995
 
MERRION RESEARCH III LIMITED (1)
6,346,613 Composition and method for enhancing paracellular transport across cell layers 2 1998
 
MOCHIDA PHARMACEUTICAL CO., LTD. (1)
6,251,873 Antisense compounds to CD14 4 1998
 
MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (1)
7,045,350 Alternatively spliced circulating tissue factor 0 2002
 
MURDOCK CHILDREN'S RESEARCH INSTITUTE (1)
6,900,186 Method for the prophylaxis and/or treatment of medical disorders 0 2000
 
NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (1)
7,741,300 Methods of using nucleic acid vector-lipid complexes 3 2005
 
NORTHWESTERN UNIVERSITY (1)
5,891,714 Cationic phospholipids for transfection 11 1995
 
NOVARTIS;CORPORATE INTELLECTUAL PROPERTY (1)
5,744,460 Combination for treatment of proliferative diseases 26 1996
 
OXFORD BIOMEDICA (UK) LIMITED (1)
6,310,045 Compositions and methods for cancer immunotherapy 2 1995
 
PFIZER PRODUCTS INC. (1)
6,828,473 Modulation of PDE11A activity 2 2001
 
PURINA MILLS, INC. (1)
6,297,027 Bovine leptin protein, nucleic acid sequences coding therefor and uses thereof 1 1996
 
REGENEMED, INC., A CALIFORNIA CORPORATION (1)
6,027,935 Gene up-regulated in regenerating liver 2 1996
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (1)
5,994,320 Antisense oligonucleotides and methods for treating central nervous system tumors 13 1997
 
RESEARCH DEVELOPMENT FOUNDATION (1)
6,784,163 Inhibition of cationic amino acid transporter protein and uses thereof 0 1999
 
RIBOGEN, INC. (1)
6,667,152 Method for selective inactivation of viral replication 26 2002
 
SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (1)
5,856,461 Oligonucleotides to inhibit the expression of isoprenyl protein transferases 2 1995
 
SOCIETY FOR RESEARCH AND INITIATIVES (SRISTI) (1)
7,666,674 Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo 16 2002
 
TAIHO PHARMACEUTICAL CO., LTD. (1)
6,034,234 Double-stranded oligonucleotide and anticancer agent containing the same as active ingredient 2 1996
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
5,869,462 Inhibition of proliferation of vascular smooth muscle cell 8 1995
 
THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH (1)
5,851,788 Nucleic acid encoding a family of acetyl-coenzyme-A transporter proteins, and products related thereto 5 1997
 
THE ROCKEFELLER UNIVERSITY (1)
5,831,051 Receptor for peptide hormones involved in energy homeostasis, and method and compositions for use thereof 0 1995
 
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (1)
5,808,036 Stem-loop oligonucleotides containing parallel and antiparallel binding domains 25 1995
 
UNITED STATES OF AMERICA (1)
5,759,782 Cellular apoptosis susceptibility protein (CSP) and antisense CSP 9 1995
 
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (1)
5,821,052 Control of the synthesis of proteins by anitisense RNA-tRNA complex 8 1994
 
UNIVERSITY TECHNOLOGY CORPORATION (1)
5,753,477 Magneto-biolistic methods 10 1996
 
WORCHESTER FOUNDATION FOR BIOMEDICAL RESEARCH (1)
6,440,660 Oligonucleotide mediated reversal of drug resistance 1 1996
 
YALE UNIVERSITY (1)
6,180,613 AAV-mediated delivery of DNA to cells of the nervous system 48 1995
 
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (1)
6,252,141 Tomato gene B polynucleotides coding for lycopene cyclase 2 1998
 
OTHER [CHECK PATENT PROFILE FOR ASSIGNMENT INFORMATION] (4)
6,008,200 Immunomodulatory oligonucleotides 1995
5,989,873 Method of detecting gene expression and/or of preventing such expression in cells 2 1997
5,994,528 Method of detecting gene expression and/or of preventing such expression in cells 0 1998
7,851,455 MN gene and protein 0 2007